Filing Details
KIORA PHARMACEUTICALS INC (NASDAQ:KPRX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 07, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:KPRX
KIORA PHARMACEUTICALS INC (KPRX) Files Quarterly Report for Q0
KIORA PHARMACEUTICALS INC (NASDAQ:KPRX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 07, 2026.
At publication ·
What changed
KIORA PHARMACEUTICALS INC (NASDAQ:KPRX) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- KIORA PHARMACEUTICALS INC (NASDAQ: KPRX) filed its quarterly report (Form 10-Q) on August 07, 2026, providing unaudited financial statements and management commentary on recent performance.
- The company's stock trades at $2.64 with a market capitalization of $7.9 million as of the filing date.
- The 10-Q filing contains information about emerging trends, updated risk factors, and changes in business conditions since the last annual filing, though specific revenue figures and financial results are not disclosed in this summary.
Market Context
KIORA PHARMACEUTICALS INC's stock currently trades at $2.64 with a market capitalization of $7.9M.
The 10-Q provides KIORA PHARMACEUTICALS INC's quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for KIORA PHARMACEUTICALS INC are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View KPRX Stock Page
Frequently Asked Questions
Where can I read KPRX's SEC filings?
Browse all filings on our KPRX SEC filings page.
What types of SEC filings does KIORA PHARMACEUTICALS INC file?
Public companies like KIORA PHARMACEUTICALS INC file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.